Stock Analysis
BML (TSE:4694) Full Year 2024 Results
Key Financial Results
- Revenue: JP¥138.0b (down 14% from FY 2023).
- Net income: JP¥6.03b (down 61% from FY 2023).
- Profit margin: 4.4% (down from 9.8% in FY 2023). The decrease in margin was driven by lower revenue.
- EPS: JP¥155 (down from JP¥396 in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
BML EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.9%.
Looking ahead, revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 5.4% growth forecast for the Healthcare industry in Japan.
Performance of the Japanese Healthcare industry.
The company's shares are up 3.9% from a week ago.
Risk Analysis
You still need to take note of risks, for example - BML has 2 warning signs we think you should be aware of.
Valuation is complex, but we're helping make it simple.
Find out whether BML is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:4694
Flawless balance sheet average dividend payer.
